Both preclinical studies on melanoma, breast, lung and colorectal cancers [255,256] and a retrospective analysis of metastatic melanoma clinical trial data showed reduced tumour growth, enhanced CD8+ T-cell function and improved OS/PFS/ORR in patients treated with metformin and ICB compared to ICB alone [257]. Here, CD8A is linked to neoplasm.